"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Triggering of Milestone Payment Conditions under the Global Strategic Collaboration Agreement between Its Wholly-owned Subsidiary SystImmune and Bristol Myers Squibb for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren)

Announcement on Voluntary Disclosure of the Triggering of Milestone Payment Conditions under the Global Strategic Collaboration Agreement between Its Wholly-owned Subsidiary SystImmune and Bristol Myers Squibb for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment